MedEdTalks
PODCASTVASCULAR INTEGRITYCMEABO MOC

Targeting Angiopoietin-2 in DME: Efficacy and Safety Data With Drs. Carl Regillo and Nancy Holekamp

Author(s)/Faculty: Carl D. Regillo, MD, FACS; Nancy M. Holekamp, MD
Release Date: 5/31/2022Expiration Date: 5/30/2023
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.25
Content Type: PodcastProvider:
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Nancy Holekamp discuss the efficacy and safety of therapies targeting Ang-2 in DME.